Category Archives: Top Market News

The Senior Officer of Health Logic Interactive (Other OTC: CHYPF) is Buying Shares

Today, the Senior Officer of Health Logic Interactive (CHYPF – Research Report), Claudio Rigatto, bought shares of CHYPF for $64K. This recent transaction increases Claudio Rigatto’s holding in the company by 151% to a total of $47.92K. In addition to

Tuesday’s Highlights at Noon: Actinium Pharmaceuticals (ATNM), Alcoa (AA), Rite Aid (RAD), Aerie Pharma (AERI), NOV (NOV)

So far Tuesday, September 21, NASDAQ is down -0.25% and the S&P is down -2.3%. Here are this morning’s most active stocks: Actinium Pharmaceuticals (ATNM – Research Report), Alcoa (AA – Research Report), Rite Aid (RAD – Research Report), Aerie

Analysts Have Conflicting Sentiments on These Healthcare Companies: Dermata Therapeutics (NASDAQ: DRMA) and Boston Scientific (NYSE: BSX)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Dermata Therapeutics (DRMA – Research Report) and Boston Scientific (BSX – Research Report). Dermata Therapeutics (DRMA) Brookline Capital Markets analyst Kumaraguru Raja initiated

The Chairman of Knight Therapeutics (Other OTC: KHTRF) is Buying Shares

Today, the Chairman of Knight Therapeutics (KHTRF – Research Report), Jonathan Ross Goodman, bought shares of KHTRF for $104.6K. In addition to Jonathan Ross Goodman, 3 other KHTRF executives reported Buy trades in the last month. See today’s analyst top

Analysts Offer Insights on Healthcare Companies: Verrica Pharmaceuticals (NASDAQ: VRCA) and Clearside Biomedical (NASDAQ: CLSD)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Verrica Pharmaceuticals (VRCA – Research Report) and Clearside Biomedical (CLSD – Research Report) with bullish sentiments. Verrica Pharmaceuticals (VRCA) In a report

H.C. Wainwright Reiterates a Buy Rating on Oncternal Therapeutics (ONCT)

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Oncternal Therapeutics (ONCT – Research Report) today and set a price target of $9.00. The company’s shares closed last Monday at $3.93. According to, Selvaraju is a 2-star analyst